药物注射治疗良性前列腺增生的研究进展  

Intraprostatic Injections for Benign Prostatic Hyperplasia

作　　者：冯煜然 韦琳 赵诣 周科宇 朱梅[1] FENG Yu-ran;WEI Lin;ZHAO Yi;ZHOU Ke-yu;ZHU Mei(Dept.of Ultrasound,The First Affiliated Hospital of Kunming Medical University,Kunming Yunnan 650032,China)

机构地区：[1]昆明医科大学第一附属医院超声科,云南昆明650032

出　　处：《昆明医科大学学报》2020年第10期162-166,共5页Journal of Kunming Medical University

基　　金：国家自然科学基金资助项目(81160178);云南省卫生科技计划资助项目(2016NS040,2017NS039);云南省科技人才和平台计划项目(2017IC054);云南省医学学科带头人培养计划项目(D-201648);昆明医科大学科技创新团队资助项目(CXTD201709)。

摘　　要：良性前列腺增生(Benign prostatic hyperplasia,BPH)好发于中老年男性,严重影响患者生活质量。前列腺内药物注射治疗BPH因创伤小、疗效好、恢复快而备受关注。不断诞生的新型注射药物,使BPH的治疗更加多元化,但注射药物的选择却因药物类型众多、疗效及风险不一而鲜有统一论述。就前列腺内注射治疗BPH的药物特性作一综述,为药物选择提供参考。Benign prostatic hyperplasia(BPH) is a common affliction among the elderly man, which have enormous impact on health-related quality of patients. Intraprostatic injections for BPH is a safety and efficacyminimally invasive treatment. The diversification of drugs brings more hope for BPH treatment.The selection of injections is rarely reviewed due to different efficacy and risk of diversity drugs.This is a literature review about intraprostatic injections for BPH, in order to provide reference for drug selection.

关 键 词：良性前列腺增生 前列腺内注射 药物特性 

分 类 号：R697.3[医药卫生—泌尿科学]